Poland· PL-100485601
Vidisic
A künstliche tränenflüssigkeit und sonstige indifferente präparate product containing carbomerum, registered in Poland by InPharm Sp. z o.o.. The same ATC class is registered in 11 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Künstliche tränenflüssigkeit und sonstige indifferente präparate is registered in 11 of 19 countries.
Countries holding a registration under ATC S01XA20 (künstliche tränenflüssigkeit und sonstige indifferente präparate), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 7 of them publish a price we can compare per daily dose
Künstliche tränenflüssigkeit und sonstige indifferente präparate · ATC S01XA20
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
URPL (Poland)- Active substance
- Carbomerum
- Manufacturer
- InPharm Sp. z o.o.
- Country
- Poland (PL)
- ATC code
- S01XA20
- ATC class
- Künstliche Tränenflüssigkeit und sonstige indifferente Präparate
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin05909991518462
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Künstliche tränenflüssigkeit und sonstige indifferente präparate in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NetherlandsCarbomeer Medcor één dosis ooggel 2 mg/gMedcor Pharmaceuticals B.V.
- SpainLIPOLASIC 2 mg/g GEL OFTALMICOBausch & Lomb S.A.
- FinlandLiposicDr. Gerhard Mann, Chem.-pharm. Fabrik GmbH
- NorwayViscotearsOrifarm AS
- SwedenViscotears 2 mg/g ÖgongelDr. Gerhard Mann Chem.-pharm. Fabrik GmbH
- IcelandVidisicGerhard Mann Dr., Chem.-pharm. Fabrik GmbH
- IrelandLiposic 2 mg/g eye gelBausch + Lomb Ireland Limited
- FranceLIPOSIC 2 mg/g, gel ophtalmiqueLABORATOIRE CHAUVIN
Authorised across Europe · EMA
The same active substance is authorised in 18 EEA countries. Names it is sold under:
- Austria · Carbomer Agepha
- Belgium · Liposic
- Germany · Carbomer Edo, Liposic
- Denmark · Viscotears
- Spain · Lipolasic
- Finland · Viscotears
- France · Aquarest, Lacrinorm
- United Kingdom (Northern Ireland) · Viscotears, Viscotears Single Dose Unit
- Greece · Liposic, Viscoter
- Ireland · Geltears, Liposic
- Iceland · Vidisic
- Italy · Lipovisc
- Luxembourg · Vidisic Edo, Vidisic®
- Netherlands · Liposic, Vidisic Carbogel
- Norway · Viscotears
- Portugal · Liposic
- Sweden · Viscotears
- Slovakia · Vidisic
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/fef2b1fb-b4da-4b43-86f3-25b0fc0132f9 GET /v1/drugs/fef2b1fb-b4da-4b43-86f3-25b0fc0132f9?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Żel do oczu",
"source": "urpl",
"strength": "2 mg/g",
"packaging": "05909991518462 ¦ OTC ¦ 150738\n1 tuba 10 g",
"substance": "Carbomerum 2 mg/g",
"common_name": "Carbomerum",
"pl_product_id": "100485601",
"pozwolenie_nr": "144/23",
"auth_procedure": "IR",
"authorisation_validity": "2028-07-18"
}See everything about künstliche tränenflüssigkeit und sonstige indifferente präparate.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.